前列腺汤治疗Ⅲ A型前列腺炎的临床观察

目的探讨前列腺汤治疗Ⅲ A型前列腺炎的疗效.方法选择符合NIH诊断标准的Ⅲ A型前列腺炎患者46例,口服中药制剂前列腺汤,1剂/d,分2次口服,疗程30 d.以NIH-CPSI评分和前列腺液(EPS)常规白细胞计数为指标,治疗前后进行疗效比较.结果NIH-CPSI总评分治疗前后分别为(32.3±7.4)分和(17.8±4.2)分(P＜0.01);疼痛或不适评分治疗前后分别为(13.2±3.6)分和(7.8±2.3)分(P＜0.01);排尿症状评分治疗前后分别为(4.5±1.2)分和(1.4±0.8)分(P＜0.01);生活质量评分治疗前后分别为(14.6±7.4)分和(8.6±3.5)分(P＜0.01);EPS中白细胞计数治疗前后分别为(20.6±2.4)个/HP和(5.6±3.2)个/HP.治愈8例,显效11例,有效20例,无效7例,总有效率84.78%.结论前列腺汤治疗Ⅲ A型前列腺炎疗效较好.

Clinical Observation of Qianliexian Decoction in the Treatmentof NIH Ⅲ A Prostatitis

OBJECTIVE: To study the efficacy of Qianliexian Decoction in the treatment of National Institute of Health (NIH) III A prostatitis. METHODS: Forty-six patients with NIH III A prostatitis were treated by oral Qianliexian Decoction 1 dose and twice a day for 30 days. The results of the treatment were evaluated according to the NIH chronic prostatitis symptom index (NIH-CPSI) and leukocyte counts in the expressed prostatic secretions (EPS). RESULTS: The overall scores before and after the treatment were (32.3 +/- 7.4) and (17.8 +/- 4.2) on NIH-CPSI (P < 0.01), (13.2 +/- 3.6) and (7.8 +/- 2.3) on pain or discomfort (P < 0.01), (4.5 +/- 1.2) and (1.4 +/- 0.8) on urinary symptoms (P < 0.01), (14.6 +/- 7.4) and (8.6 +/- 3.5) on the quality of life (P < 0.01), and (20.6 +/- 2.4) /HP and (5.6 +/- 3.2)/HP on leukocyte counts, respectively. The decoction cured 8 of the patients and was shown to be obviously effective in 11 cases, effective in 20 and ineffective in 7, with a total efficacy rate of 84.78%. CONCLUSION: Qianliexian Decoction is quite effective for the treatment of NIH III A prostatitis.